• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
ALEXMED ePosters
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 7 (2025)
Volume Volume 6 (2024)
Issue Issue 3
Issue Issue 2
Issue Issue 1
Volume Volume 5 (2023)
Volume Volume 4 (2022)
Volume Volume 3 (2021)
Volume Volume 2 (2020)
Volume Volume 1 (2019)
Abd El-Aal, T., Eldeeb, M., Abdel-Fattah, Y., Tawfik, N., Elsanour, K. (2024). SERUM ELAFIN AS A MARKER OF SEVERITY IN SKIN PSORIASIS AND PSORIATIC ARTHRITIS. ALEXMED ePosters, 6(3), 50-51. doi: 10.21608/alexpo.2024.313626.1926
Tarek Hussein Abd El-Aal; Marwa Elsaeed Eldeeb; Yousra Hisham Abdel-Fattah; Nourane Tawfik; Kholod Ibrahim Elsanour. "SERUM ELAFIN AS A MARKER OF SEVERITY IN SKIN PSORIASIS AND PSORIATIC ARTHRITIS". ALEXMED ePosters, 6, 3, 2024, 50-51. doi: 10.21608/alexpo.2024.313626.1926
Abd El-Aal, T., Eldeeb, M., Abdel-Fattah, Y., Tawfik, N., Elsanour, K. (2024). 'SERUM ELAFIN AS A MARKER OF SEVERITY IN SKIN PSORIASIS AND PSORIATIC ARTHRITIS', ALEXMED ePosters, 6(3), pp. 50-51. doi: 10.21608/alexpo.2024.313626.1926
Abd El-Aal, T., Eldeeb, M., Abdel-Fattah, Y., Tawfik, N., Elsanour, K. SERUM ELAFIN AS A MARKER OF SEVERITY IN SKIN PSORIASIS AND PSORIATIC ARTHRITIS. ALEXMED ePosters, 2024; 6(3): 50-51. doi: 10.21608/alexpo.2024.313626.1926

SERUM ELAFIN AS A MARKER OF SEVERITY IN SKIN PSORIASIS AND PSORIATIC ARTHRITIS

Article 1, Volume 6, Issue 3, July 2024, Page 50-51  XML
Document Type: Preliminary preprint short reports of original research
DOI: 10.21608/alexpo.2024.313626.1926
View on SCiNiTO View on SCiNiTO
Authors
Tarek Hussein Abd El-Aal1; Marwa Elsaeed Eldeeb1; Yousra Hisham Abdel-Fattahorcid 2; Nourane Tawfik3; Kholod Ibrahim Elsanour email 1
1Department of Dermatology, Venereology, and Andrology, Faculty of Medicine, Alexandria University, Egypt.
2Department of Physical Medicine, Rheumatology and Rehabilitation, Faculty of medicine, Alexandria university, Egypt.
3Department of Clinical and Chemical Pathology, Faculty of Medicine, Alexandria University, Egypt.
Abstract
Psoriasis is believed to have multifactorial pathogenesis in which genetic, environmental, and immunological factors contribute to the disease. Elafin, an anti-inflammatory serine protease inhibitor, is one of the natural AMPs and is generated by immune cells, keratinocytes, and epithelial cells.) Elafin is hardly present in healthy skin. However, it is highly expressed in psoriatic patients' urine, sputum, and epidermis.( Psoriatic Arthritis (PsA) is an inflammatory musculoskeletal illness that can be associated with all types of psoriasis of varying severity.

AIM:
The present study assessed serum Elafin in psoriatic patients, and its relation to the severity of skin disease as well as its association with Psoriatic Arthritis (PsA).

PATIENTS AND METHODS:
This cross-sectional study included forty psoriatic patients and forty healthy individuals. Serum Elafin was measured in all subjects using ELISA (Enzyme-Linked Immunosorbent Assay), skin disease was assessed using the PASI score, and psoriatic arthritis was assessed using the DASPA score.
Keywords
Elafin; psoriasis; psoriatic arthritis
Supplementary Files
download 1926 10.pdf
Statistics
Article View: 74
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.